New pyrano-pyridine conjugates as potential anticancer agents: design, synthesis and computational studies.

ABSTRACT:

Aim

New pyrano[3,2-c]pyridine 4a-h, 5-8 and pyrano[2,3-d]pyrimidin 9a,b series were designed and chemically synthesized.

Methodology

Using the standard drug doxorubicin, the novel chemical entities have been assessed in vitro as potential anticancer prospects on cell lines from liver, breast, colon, and lung cancer along with examining their inhibitory behaviors upon both EGFR and VEGFR-2 kinases.

Results & conclusion

Compared to erlotinib (IC₅₀ = 0.18 µM), compounds 8a and 8b demonstrated the highest anticancer activity with IC₅₀ Values 0.23 and 0.15 µM, respectively). Further, derivative 8a illustrated encouraging inhibitory characteristics against EGFR and VEGFR-2 (IC₅₀ = 1.21 and 2.65 μM, respectively). A computational study was us

SUBMITTER: Srour AM 

PROVIDER: S-EPMC11734389 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature